Sector News

Edwards Announces Board Changes

February 11, 2015
Life sciences
/PRNewswire/ – Edwards Lifesciences Corporation, the global leader in the science of heart valves and hemodynamic monitoring, today announced two changes to the company’s board of directors. Kieran T. Gallahue, chairman and chief executive officer of CareFusion Corporation, has been appointed to Edwards’ board, effective immediately. Current director Mike R. Bowlin has expressed his desire to retire from the board and will not seek re-election at the annual stockholder meeting in May. 
 
“We are fortunate that the timing of these individual decisions enables Edwards to allow a smooth transition and benefit from both Mike and Kieran during the next several months, working in partnership with our talented board,” said Michael A. Mussallem, Edwards’ chairman and CEO. 
 
Bowlin joined Edwards’ board of directors in 2000, when Edwards was established as an independent, publicly held corporation. He has served as a member and chairman of the compensation and governance committee and presiding director. Bowlin retired from the Atlantic Richfield Company in 2000, after holding positions including chairman of the board, CEO and president. 
 
“I’d like to take this opportunity to express my sincere gratitude to Mike for his outstanding service to our board of directors,” said Mussallem. “He is extremely knowledgeable about the complex international business environment and brought large-scale experience on diverse compensation and incentive matters. We wish Mike the best in his upcoming retirement from the board, and thank him for his valuable insight and guidance as we have built a record of success for Edwards. 
 
“I would also like to welcome Kieran to a strong board that will benefit from his 20 years of executive management experience in medical technology and his leadership roles on other public company boards and committees,” said Mussallem. “Kieran has led a number of innovative companies and been an active advocate of the value of medical technology, and we look forward to his contributions in helping to advise Edwards as we pursue our unique focused innovation strategy.” 
 
Since 2011, Gallahue has served as chairman and CEO of CareFusion, a global corporation serving the healthcare industry with products and services that help hospitals measurably improve the safety and quality of care. Prior, he served as president and, later, as CEO of ResMed, Inc. Gallahue is currently on the executive committee of the board of the Advanced Medical Technology Association (AdvaMed). 
 
Source: Edwards Lifesciences 

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach